Effect of biologic agents and inflammation on lipid levels and cardiovascular risk in rheumatoid arthritis patients

Rheumatoid Arthritis

Is a 1-year course of methotrexate in patients with arthralgia at-risk for rheumatoid arthritis cost-effective? A cost-effectiveness analysis of the randomised, placebo-controlled TREAT EARLIER trial

Ann Rheum Dis

van Mulligen E, Bour SS, Goossens LMA, de Jong PHP, Rutten-van Mölken M, van der Helm-van Mil A

doi: 10.1136/ard-2024-226286

Rheumatoid Arthritis

Impact of systemic inflammation and disease activity on the incidence of interstitial lung disease in patients with rheumatoid arthritis - a nested case-control study within the German biologics register RABBIT

Arthritis Res Ther

Ramien R, Rudi T, Alten R, Krause A, Schneider M, Schaefer M, Strangfeld A, Meissner Y

doi: 10.1186/s13075-024-03449-9

Psoriatic ArthritisRheumatoid Arthritis

The effect of biological treatment on female fertility: A cohort study of women with rheumatoid arthritis and psoriatic arthritis

Semin Arthritis Rheum

Herzberger EH, Hornik-Lurie T, Levi Y, Miller N, Wiser A, Hershko-Klement A

doi: 10.1016/j.semarthrit.2024.152608

Rheumatoid Arthritis

Association of patient- and hospital-level predictors with patterns of initial treatment in patients with Rheumatoid Arthritis: findings from a national cohort study

Rheumatology (Oxford)

Yang Z, Alveyn E, Russell M, Bechman K, Coalwood C, Price E, Abhishek A, Norton S, Galloway J

doi: 10.1093/rheumatology/keae717

Rheumatoid Arthritis

Risk of Incident Heart Failure and Heart Failure Subtypes in Patients with Rheumatoid Arthritis

Arthritis Care Res (Hoboken)

Kawano Y, Weber BN, Weisenfeld D, Jeffway MI, Cai T, McDermott GC, Liu Q, Sparks JA, Stuart J, Joseph J, Cai T, Liao KP

doi: 10.1002/acr.25481

Rheumatoid Arthritis

Impact of RA treatment strategies on lipids and vascular inflammation in rheumatoid arthritis: a secondary analysis of the TARGET randomized active comparator trial

Arthritis Res Ther

Liao KP, Rist P, Giles J, Santacroce L, Connelly MA, Glynn RJ, Ridker P, Tawakol A, Bathon J, Solomon DH

doi: 10.1186/s13075-024-03352-3

Rheumatoid Arthritis

Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports

Semin Arthritis Rheum

Goldman A, Galper BL, Druyan A, Grossman C, Sharif K, Shechtman L, Moshkovits Y, Lahat A, Ben-Zvi I

doi: 10.1016/j.semarthrit.2024.152461

Rheumatoid Arthritis

New onset work disability in rheumatoid arthritis is an underrecognized cardiovascular risk factor: A retrospective cohort study using the CorEvitas registry

Semin Arthritis Rheum

Spandorfer R, Kane K, Pappas DA, Kremer J, Reed G, Curtis JR, Navarro-Millán I

doi: 10.1016/j.semarthrit.2024.152559

Rheumatoid Arthritis

Cardiovascular safety of the class of JAK inhibitors or tocilizumab compared with TNF inhibitors in patients with rheumatoid arthritis: Systematic review and a traditional and Bayesian network meta-analysis of randomized clinical trials

Semin Arthritis Rheum

Pugliesi A, Oliveira DGC, Filho VAS, Machado JO, Pereira AG, Bichuette JCS, Sachetto Z, de Carvalho LSF, Bertolo MB

doi: 10.1016/j.semarthrit.2024.152563

Related content

Is a 1-year course of methotrexate in patients with arthralgia at-risk for rheumatoid arthritis cost-effective? A cost-effectiveness analysis of the randomised, placebo-controlled TREAT EARLIER trial

Impact of systemic inflammation and disease activity on the incidence of interstitial lung disease in patients with rheumatoid arthritis - a nested case-control study within the German biologics register RABBIT

The effect of biological treatment on female fertility: A cohort study of women with rheumatoid arthritis and psoriatic arthritis

Association of patient- and hospital-level predictors with patterns of initial treatment in patients with Rheumatoid Arthritis: findings from a national cohort study

Risk of Incident Heart Failure and Heart Failure Subtypes in Patients with Rheumatoid Arthritis

Impact of RA treatment strategies on lipids and vascular inflammation in rheumatoid arthritis: a secondary analysis of the TARGET randomized active comparator trial

Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports

New onset work disability in rheumatoid arthritis is an underrecognized cardiovascular risk factor: A retrospective cohort study using the CorEvitas registry

Cardiovascular safety of the class of JAK inhibitors or tocilizumab compared with TNF inhibitors in patients with rheumatoid arthritis: Systematic review and a traditional and Bayesian network meta-analysis of randomized clinical trials